Novavax (NVAX) Stock: Buy, Sell, or Hold?
$10.20
-0.69 (-6.34%)
▼
5d:
+5.37%
30d:
-19.43%
90d:
+28.14%
QUANTITATIVE VERDICT
BUY
MODERATE Confidence (86%)
Quality Score
61/100
Position
SLIGHTLY LOW
30-Day Fair Range
$9.87 – $12.01
Position: SLIGHTLY LOW
Forward P/E & Valuation
-30.3x
CHEAP
vs 35.1x historical avg
Wall Street Target
$14.11
+38.3% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$9.39 / $11.20
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
💡 BUY OPPORTUNITY: NVAX shows positive signals but monitor for confirmation. Market pricing in 0% growth. Moderate conviction.
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Nov 10, 2026 at $10.40 · last confirmed Nov 10, 2026
Strength: 6.7/10
Get Alerted When NVAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: NVAX is currently trading at $10.20, which is considered slightly low relative to its 30-day fair value range of $9.87 to $12.01. From a valuation perspective, the stock is trading at a discount (Forward PE: -30.3) compared to its historical average (35.1). At these levels, the market is pricing in 0% annual earnings growth.
Technical Outlook: Technically, NVAX is in a strong uptrend. Immediate support is located at $9.39, while resistance sits at $11.20. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: NVAX scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $14.11 (+38.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NVAX is in a strong uptrend. Immediate support is located at $9.39, while resistance sits at $11.20. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: NVAX scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $14.11 (+38.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$9.87 -
$12.01
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
85.7%
Trading Range & Key Levels
30-Day Trading Range
$9.87 -
$12.01
Current vs Trading Range
SLIGHTLY LOW
Support Level
$9.39
Resistance Level
$11.20
Current Trend
Strong Uptrend
Technical data as of
Nov 10, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (65/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.3%)
- BULLISH: Trading 38.3% below Wall St target ($14.11)
- BULLISH: Bottoming setup score 65/100 — corrected, stabilizing, and turning up
Fundamental Context
Forward P/E (Next Year Est.)
-30.32
Wall Street Target
$14.11
(+38.3%)
Revenue Growth (YoY)
-3.0%
Earnings Growth (YoY)
-38.1%
Profit Margin
-18.6%
PE vs Historical
-30.3 vs 35.1
CHEAP
Share NVAX Analysis
Share this live NVAX analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (NVAX)
Bullish
5 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
4 msgs
24h retail stream
Last Tracked
Nov 11, 2026
Daily AI digest
AI Retail Discussion Summary:
Novavax reported Q3 revenue ahead of estimates, driven by a one-time milestone payment from Sanofi. Despite the revenue outperformance, sales declined year over year, and the market responded negatively. Novavax aims to achieve non-GAAP profitability by reducing expenses.
Key Retail Themes:
Revenue outperformance
Cost reductions and profitability
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 8:34 AM ET
Data refreshes hourly during market hours. Next update: 9:34 AM
Data refreshes hourly during market hours. Next update: 9:34 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$107 | 62 BUY |
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$194 | 41 HOLD |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$689 | 55 HOLD |
|
KURA
Kura Oncology Inc |
STRONG BUY
16 analysts |
$32 | 60 BUY |
|
RZLT
Rezolute Inc |
STRONG BUY
11 analysts |
$10 | 72 BUY |
Advanced NVAX Option Strategies
Professional options setups generated by AI based on today's NVAX price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive NVAX Research Pages
